Tecan Group AG - Asset Resilience Ratio

Latest as of June 2025: 20.48%

Tecan Group AG (TECN) has an Asset Resilience Ratio of 20.48% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Tecan Group AG debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CHF397.00 Million
≈ $501.92 Million USD Cash + Short-term Investments

Total Assets

CHF1.94 Billion
≈ $2.45 Billion USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Tecan Group AG's Asset Resilience Ratio has changed over time. See Tecan Group AG (TECN) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Tecan Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Tecan Group AG.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CHF255.66 Million 13.19%
Short-term Investments CHF141.34 Million 7.29%
Total Liquid Assets CHF397.00 Million 20.48%

Asset Resilience Insights

  • Good Liquidity Position: Tecan Group AG maintains a healthy 20.48% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Tecan Group AG Industry Peers by Asset Resilience Ratio

Compare Tecan Group AG's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Alcon AG
SW:ALC
Medical Instruments & Supplies 0.26%
iRay Technology Co Ltd
SHG:688301
Medical Instruments & Supplies 0.68%
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Medical Instruments & Supplies 29.19%
Jiangsu Nanfang Medical
SHG:603880
Medical Instruments & Supplies 2.27%
SDI Ltd
AU:SDI
Medical Instruments & Supplies 6.36%
I.Ceram SA
PA:ALICR
Medical Instruments & Supplies -1.61%
Ansell Ltd
AU:ANN
Medical Instruments & Supplies 4.42%
Nanosonics Ltd
AU:NAN
Medical Instruments & Supplies 51.82%

Annual Asset Resilience Ratio for Tecan Group AG (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Tecan Group AG.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 19.14% CHF406.01 Million
≈ $513.30 Million
CHF2.12 Billion
≈ $2.68 Billion
+1.47pp
2023-12-31 17.67% CHF366.42 Million
≈ $463.26 Million
CHF2.07 Billion
≈ $2.62 Billion
+4.09pp
2022-12-31 13.57% CHF293.24 Million
≈ $370.73 Million
CHF2.16 Billion
≈ $2.73 Billion
+1.74pp
2021-12-31 11.84% CHF241.91 Million
≈ $305.84 Million
CHF2.04 Billion
≈ $2.58 Billion
-29.82pp
2020-12-31 41.65% CHF470.92 Million
≈ $595.37 Million
CHF1.13 Billion
≈ $1.43 Billion
+36.28pp
2019-12-31 5.37% CHF50.50 Million
≈ $63.85 Million
CHF939.77 Million
≈ $1.19 Billion
+5.26pp
2018-12-31 0.11% CHF977.00K
≈ $1.24 Million
CHF857.67 Million
≈ $1.08 Billion
-0.01pp
2017-12-31 0.13% CHF1.02 Million
≈ $1.29 Million
CHF803.96 Million
≈ $1.02 Billion
-33.80pp
2016-12-31 33.93% CHF249.78 Million
≈ $315.79 Million
CHF736.16 Million
≈ $930.71 Million
+33.73pp
2015-12-31 0.20% CHF1.27 Million
≈ $1.60 Million
CHF641.48 Million
≈ $811.01 Million
-0.13pp
2014-12-31 0.33% CHF1.82 Million
≈ $2.31 Million
CHF552.26 Million
≈ $698.21 Million
--
pp = percentage points

About Tecan Group AG

SW:TECN Switzerland Medical Instruments & Supplies
Market Cap
$1.89 Billion
CHF1.49 Billion CHF
Market Cap Rank
#6818 Global
#92 in Switzerland
Share Price
CHF117.70
Change (1 day)
+1.99%
52-Week Range
CHF114.70 - CHF176.30
All Time High
CHF586.60
About

Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments, Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, NGS reagents, immunoassays and antibodies, … Read more